Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Research analysts at Leerink Partnrs increased their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued to ...

Meeting to be held in New York on March 18 at 6 pm hosted by Truist. Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings firms that are covering the stock, MarketBeat Ratings reports.

Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint, with SYMBRAVO ...

On Tuesday, 04 March 2025, Axsome Therapeutics (NASDAQ: AXSM) presented at the TD Cowen 45th Annual Healthcare Conference. The... ByInvesting.com • 06 Mar 2025 H.C. Wainwright maintains Axsome stock ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ ... "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Axsome Therapeutics (NASDAQ:AXSM) reported Q4 EPS of ($1.41), $0.28 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $24.37 million versus the ...